As a result Novo Nordisk and the National Institutes of Health funded a randomised, double-blind, controlled trial to look at the issue
Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: The XENSOR Study
So, maybe its time to get this dynamic duo working for you
The SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major adverse cardiovascular events in patients with obesity
But most mention deeper in the article the redheads were really mice
The doses tested included 0.5, 1, 2, 5, 10, 20, 50, and 100 nmol/kg/day administered subcutaneously just before the start of the dark cycle